Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : JNCCN Gradishar, W. J., Anderson, B. O., Balassanian, R. n., Blair, S. L., Burstein, H. J., Cyr, A. n., Elias, A. D., Farrar, W. B., Forero, A. n., Giordano, S. H., Goetz, M. P., Goldstein, L. J., Isakoff, S. J., Lyons, J. n., Marcom, P. K., Mayer, I. A., McCormick, B. n., Moran, M. S., O'Regan, R. M., Patel, S. A., Pierce, L. J., Reed, E. C., Salerno, K. E., Schwartzberg, L. S., Sitapati, A. n., Smith, K. L., Smith, M. L., Soliman, H. n., Somlo, G. n., Telli, M. L., Ward, J. H., Kumar, R. n., Shead, D. A. 2018; 16 (3): 310–20


Ductal carcinoma in situ (DCIS) of the breast represents a heterogeneous group of neoplastic lesions in the breast ducts. The goal for management of DCIS is to prevent the development of invasive breast cancer. This manuscript focuses on the NCCN Guidelines Panel recommendations for the workup, primary treatment, risk reduction strategies, and surveillance specific to DCIS.

View details for DOI 10.6004/jnccn.2018.0012

View details for PubMedID 29523670